Arun Venkat, MD
Dermatology · Oceanside, CANPI 1952436354
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $650 and has fallen 55.4% since, to $290 in 2025. That places this record below the midpoint for dermatology clinicians in CA, where the typical reported total is $1,655.
Across 73 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$343
- AbbVie$306
- Regeneron Healthcare Solutions, Inc.$175
- Johnson & Johnson$168
- Almirall LLC$154
- Novartis$142
- plus $788 from 15 others
Across 43 payments — averaging $3897.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo Pharmaceuticals Inc.$87K
- Pfizer$81K
What the payments were for
- Food & beverage$2,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 5 | $343 |
| AbbVie(2 entities) | 18 | $306 |
| Regeneron Healthcare Solutions, Inc. | 6 | $175 |
| Johnson & Johnson | 2 | $168 |
| Almirall LLC | 3 | $154 |
| Novartis | 3 | $142 |
| LEO Pharma Inc. | 5 | $140 |
| Pfizer | 6 | $116 |
| Sanofi | 5 | $106 |
| Lilly USA, LLC | 3 | $76 |
| Dermavant Sciences, Inc. | 3 | $61 |
| UCB, Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 2 | $44 |
| Incyte Corporation | 2 | $42 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Biofrontera Inc. | 2 | $31 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Strata Skin Sciences, Inc. | 1 | $16 |
| Sensus Healthcare, Inc. | 1 | $15 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$130
- AKLIEF$111
- SOOLANTRA$111
- EPIDUO FORTE$111
- NEMLUVIO$104
How this compares
$2,077 in reported general payments places this provider in the 50th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $214,022 |
| Humira(Cf) PenAdalimumab | 19 | $124,161 |
| Dupixent SyringeDupilumab | 16 | $87,993 |
| Clobetasol Propionate | 158 | $7,949 |
| Tacrolimus | 23 | $3,924 |
| Calcipotriene | 14 | $2,671 |
| Fluorouracil | 30 | $2,188 |
| Mometasone Furoate | 130 | $2,157 |
| Clotrimazole | 64 | $1,084 |
| Triamcinolone Acetonide | 80 | $1,083 |
| Hydroxychloroquine Sulfate | 14 | $982 |
| Betamethasone Dipropionate | 16 | $979 |
| Fluocinonide | 20 | $931 |
| Hydroxyzine Hcl | 29 | $623 |
| Terbinafine Hcl | 21 | $508 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Oceanside
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
- April ArmstrongLos Angeles$2.3M
- Jeffrey CrowleyBakersfield$2.1M
- Jashin WuCorona$2M
- Raja SivamaniSacramento$1.9M
- Tien NguyenFountain Valley$1.2M
- Tina BhutaniSan Francisco$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.